Literature DB >> 24057863

Cardiovascular pharmacology core reviews: aspirin.

Michael A Gaglia1, Leonardo Clavijo.   

Abstract

Acetylsalicylic acid, or aspirin, is perhaps the most well-studied drug in human history, but controversy persists regarding both optimal dose and its use in the primary prevention of atherothrombotic events. This article reviews the following: the effect of aspirin upon the cyclooxygenase pathway; clinical trials of aspirin for both secondary and primary prevention; prospective and retrospective studies of aspirin dose; the potential interaction between aspirin and ticagrelor; and the concept of aspirin resistance. It concludes with a review of major society guidelines regarding aspirin and offers a perspective on the evidence-based use of aspirin in clinical practice.

Entities:  

Keywords:  aspirin; cardiovascular diseases; drug resistance; primary prevention; secondary prevention

Mesh:

Substances:

Year:  2013        PMID: 24057863     DOI: 10.1177/1074248413503043

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  3 in total

1.  Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling.

Authors:  Samuel Chege Gitau; Xuelian Li; Dandan Zhao; Zhenfeng Guo; Haihai Liang; Ming Qian; Lifang Lv; Tianshi Li; Bozhi Xu; Zhiguo Wang; Yong Zhang; Chaoqian Xu; Yanjie Lu; Zhiming Du; Hongli Shan; Baofeng Yang
Journal:  Front Med       Date:  2015-12-02       Impact factor: 4.592

2.  Editorial on low-dose acetylsalicylic acid treatment and impact on short-term mortality in Staphylococcus aureus bloodstream infection: a propensity score-matched cohort study.

Authors:  Christian Schoergenhofer; Michael Schwameis; Heimo Lagler; Bernd Jilma
Journal:  Ann Transl Med       Date:  2016-05

Review 3.  PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.

Authors:  Danielle Duffy; Bridget Rooney; Suzanne Adams; David J Whellan
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.